GlobeNewswire: ChromaDex Corporation Contains the last 10 of 210 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T03:44:30ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/03/23/2004581/0/en/Cellular-Health-Market-Leader-Tru-Niagen-Launches-Online-in-Australia.html?f=22&fvtc=4&fvtv=25556Cellular Health Market Leader Tru Niagen® Launches Online in Australia2020-03-23T10:30:00Z<![CDATA[ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia]]>https://www.globenewswire.com/news-release/2020/03/12/1999927/0/en/ChromaDex-Corrects-Statements-Made-by-an-Unaffiliated-Third-Party-Regarding-its-Product-and-COVID-19.html?f=22&fvtc=4&fvtv=25556ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-192020-03-12T20:44:22Z<![CDATA[LOS ANGELES, March 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. There are no published human clinical studies evaluating the effects of Tru Niagen® supplementation with the Coronavirus. As such, no health claims can be made related to COVID-19 at this time.]]>https://www.globenewswire.com/news-release/2020/03/10/1998335/0/en/CHROMADEX-CORPORATION-REPORTS-2019-FINANCIAL-RESULTS.html?f=22&fvtc=4&fvtv=25556CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS2020-03-10T20:01:00Z<![CDATA[Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018]]>https://www.globenewswire.com/news-release/2020/02/27/1991721/0/en/New-Niagen-Nicotinamide-Riboside-NR-Study-Deepens-Understanding-of-NAD-Decline-and-Hearing-Loss-in-Animal-Model.html?f=22&fvtc=4&fvtv=25556New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model2020-02-27T11:30:00Z<![CDATA[Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models]]>https://www.globenewswire.com/news-release/2020/02/25/1989865/0/en/ChromaDex-to-Report-Fourth-Quarter-2019-Financial-Results-on-Tuesday-March-10-2020.html?f=22&fvtc=4&fvtv=25556ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 20202020-02-25T11:30:00Z<![CDATA[LOS ANGELES, Feb. 25, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended Dec. 31, 2019. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.]]>https://www.globenewswire.com/news-release/2020/02/12/1983671/0/en/ChromaDex-Partners-with-Personalized-Nutrition-Company-Persona-Nutrition-Expanding-Global-Partnership-with-Nestl%C3%A9-Health-Science.html?f=22&fvtc=4&fvtv=25556ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science2020-02-12T11:30:00Z<![CDATA[Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service]]>Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery servicePersona Nutrition offering Tru Niagen®https://www.globenewswire.com/news-release/2020/02/03/1978594/0/en/ChromaDex-Launches-New-Line-of-High-Purity-Cannabinoid-CBD-Reference-Standards-Available-for-Research-and-Analytical-Testing-Worldwide.html?f=22&fvtc=4&fvtv=25556ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide2020-02-03T11:30:00Z<![CDATA[ChromaDex launches new research tools for the CBD industry with line of reference standards ChromaDex launches new research tools for the CBD industry with line of reference standards]]>https://www.globenewswire.com/news-release/2020/01/15/1970761/0/en/ChromaDex-Achieves-New-Regulatory-Milestones-in-the-European-Union-Australia.html?f=22&fvtc=4&fvtv=25556ChromaDex Achieves New Regulatory Milestones in the European Union & Australia2020-01-15T11:30:00Z<![CDATA[ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity]]>https://www.globenewswire.com/news-release/2020/01/06/1966317/0/en/First-of-its-Kind-Clinical-Study-Initiated-to-Investigate-Potential-Benefits-of-Nicotinamide-Riboside-Combined-with-Exercise-in-Older-Adults-with-Hypertension.html?f=22&fvtc=4&fvtv=25556First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension2020-01-06T11:30:00Z<![CDATA[Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3 Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3]]>https://www.globenewswire.com/news-release/2019/12/16/1960803/0/en/ChromaDex-Wins-Nutritional-Outlook-s-2019-Best-of-Industry-Ingredient-Supplier-Award-for-Niagen.html?f=22&fvtc=4&fvtv=25556ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®2019-12-16T11:30:00Z<![CDATA[LOS ANGELES, Dec. 16, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen® (nicotinamide riboside). The state of the science surrounding Niagen will be presented during the ChromaDex Scientific Advisory Board (SAB) annual meeting taking place Dec. 16-17 in Los Angeles, CA.]]>